MUNICH, GERMANY / ACCESSWIRE / November 13, 2017 / Definiens, the leader in Tissue Phenomics® announced the strengthening of its global commercial leadership team by appointing Jacques Corriveau as ...
MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel ...
MUNICH, GERMANY / ACCESSWIRE / July 26, 2018 / Definiens AG, the leader in Tissue Phenomics® is very pleased to announce the appointment of Mr. Markus Schunk as Chief Operating Officer, a Management ...
MUNICH, Germany & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq:CLRT) and Definiens, Inc. jointly announced today that they established a strategic partnership to employ a series of ...
Tissue Phenomics approach accelerates clinical trial assay development & patient profiling MUNICH, Oct. 3, 2018 /PRNewswire/ -- Definiens, the Tissue Phenomics company, has announced the first-ever ...
Collaboration to bolster end-to-end services from assay development to confident informed clinical decision making MUNICH and KASSEL, Germany, June 20, 2019 /PRNewswire/ -- Definiens, a leading ...
Wellington Partners, a leading pan-European venture capital firm, today announced that it acted as lead investor in a € 15 million growth financing round at Definiens AG, Munich, Germany. Wellington ...
Definiens, the number one Enterprise Image Intelligence™ company, has announced the introduction of a new multi-dimensional image analysis platform. Software applications built on Definiens XD extract ...
Following the recent financing round, Dr. Möller will guide the expansion of Definiens' current business and the development and commercialization of innovative products for clinical Digital Pathology ...
Definiens, a Munich-based developer of image analysis techniques and specialists in the growing field of digital pathology, recently closed a private funding round worth €10 million. The funds will ...
MedImmune enters into an agreement to acquire the image analysis and data mining company. MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to ...